ZA200405029B - 17α-Alkyl-17β-oxy-estratrienes and intermediates for the production thereof, and use of said 17α-alkyl-17β-oxy-estratrienes for producing medicaments and pharmaceutical preparations - Google Patents
17α-Alkyl-17β-oxy-estratrienes and intermediates for the production thereof, and use of said 17α-alkyl-17β-oxy-estratrienes for producing medicaments and pharmaceutical preparationsInfo
- Publication number
- ZA200405029B ZA200405029B ZA200405029A ZA200405029A ZA200405029B ZA 200405029 B ZA200405029 B ZA 200405029B ZA 200405029 A ZA200405029 A ZA 200405029A ZA 200405029 A ZA200405029 A ZA 200405029A ZA 200405029 B ZA200405029 B ZA 200405029B
- Authority
- ZA
- South Africa
- Prior art keywords
- estratrienes
- oxy
- alkyl
- intermediates
- production
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10159217A DE10159217A1 (de) | 2001-11-27 | 2001-11-27 | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200405029B true ZA200405029B (en) | 2009-07-29 |
Family
ID=7707804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200405029A ZA200405029B (en) | 2001-11-27 | 2004-06-24 | 17α-Alkyl-17β-oxy-estratrienes and intermediates for the production thereof, and use of said 17α-alkyl-17β-oxy-estratrienes for producing medicaments and pharmaceutical preparations |
| ZA200407868A ZA200407868B (en) | 2001-11-27 | 2004-09-29 | 17alpha-Alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200407868A ZA200407868B (en) | 2001-11-27 | 2004-09-29 | 17alpha-Alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7018994B2 (ko) |
| EP (2) | EP1916254A3 (ko) |
| JP (3) | JP2005513039A (ko) |
| KR (1) | KR100956912B1 (ko) |
| CN (2) | CN1325507C (ko) |
| AR (1) | AR037674A1 (ko) |
| AT (1) | ATE396198T1 (ko) |
| AU (1) | AU2002360949A1 (ko) |
| BR (1) | BR0214469A (ko) |
| CA (1) | CA2468412C (ko) |
| CY (1) | CY1108279T1 (ko) |
| DE (2) | DE10159217A1 (ko) |
| DK (1) | DK1448591T3 (ko) |
| ES (1) | ES2307819T3 (ko) |
| HK (2) | HK1077832A1 (ko) |
| IL (2) | IL162200A0 (ko) |
| MX (1) | MXPA04005015A (ko) |
| NO (2) | NO326241B1 (ko) |
| PE (1) | PE20030727A1 (ko) |
| PL (1) | PL207955B1 (ko) |
| PT (1) | PT1448591E (ko) |
| RU (2) | RU2285009C2 (ko) |
| TW (1) | TWI256891B (ko) |
| UY (1) | UY27552A1 (ko) |
| WO (1) | WO2003045972A1 (ko) |
| ZA (2) | ZA200405029B (ko) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10159217A1 (de) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| TW200617019A (en) | 2004-07-27 | 2006-06-01 | Sicor Inc | A process for the preparation of 7α-alkylated 19-norsteroids |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| AU2007284759B2 (en) | 2006-08-09 | 2010-10-28 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
| JP4724073B2 (ja) | 2006-08-17 | 2011-07-13 | 富士通株式会社 | レジストパターンの形成方法、半導体装置及びその製造方法 |
| DE102007049630A1 (de) | 2007-10-11 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| DE102007023614A1 (de) | 2007-05-21 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| CN105688191A (zh) | 2007-04-23 | 2016-06-22 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
| DE102007032800A1 (de) | 2007-07-10 | 2009-01-15 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| EP2033948A1 (en) * | 2007-08-30 | 2009-03-11 | Bayer Schering Pharma Aktiengesellschaft | Process for preparing Estrogen-antagonistic 11beta-Fluoro-17alpha-alkylestra-1,3,5 (10)-triene-3, 17-diols having a 7alpha-(xi-Alkylamino-omega-perfluoroalkyl)alkyl side chain and alpha-Alkyl(amino)-omega-perfluoro(alkyl)alkanes and processes for their preparation |
| DE102007058747A1 (de) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| EP2070942A1 (de) | 2007-12-13 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Aromatisierung von 19-Nor-androst-4-en-3-onen zu Estra-1,3,5(10)-trienen |
| EP2070909A1 (de) | 2007-12-15 | 2009-06-17 | Bayer Schering Pharma AG | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| EP2070941A1 (en) | 2007-12-14 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Stereoselective synthesis of selective estrogen receptor down-regulators |
| DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
| DE102008057230A1 (de) | 2008-11-11 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin |
| EP2258375A1 (de) * | 2009-06-04 | 2010-12-08 | Bayer Schering Pharma Aktiengesellschaft | 17B-alkyl-17alpha-oxy-estratriene |
| DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034362A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034525A1 (de) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| MX352878B (es) | 2009-09-28 | 2017-12-13 | Intarcia Therapeutics Inc | Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco. |
| DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| DE102010007719A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| US11576891B2 (en) | 2010-06-16 | 2023-02-14 | Endorecherche, Inc. | Methods of treating or preventing estrogen-related diseases |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| DE102011004899A1 (de) | 2011-03-01 | 2012-09-06 | Bayer Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| EP2983671B1 (en) | 2013-04-11 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Progesterone receptor antagonist dosage form |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| CN113598842A (zh) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | 植入物放置和移除系统 |
| MX2018014016A (es) | 2016-05-16 | 2019-08-01 | Intarcia Therapeutics Inc | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
| US11624095B2 (en) | 2017-09-27 | 2023-04-11 | Case Western Reserve University | Method of quantifying HIV reservoirs by induced transcription based sequencing |
| RU2750488C1 (ru) * | 2020-06-03 | 2021-06-28 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | 1,2,4-Оксадиазольные производные дезоксихолевой кислоты, обладающие простатопротекторным действием, гипохолестеринемической и противовоспалительной активностями |
| CN116535454A (zh) * | 2023-04-28 | 2023-08-04 | 香港中文大学（深圳） | 氟维司群类化合物及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36654A (en) | 1970-04-24 | 1974-07-31 | Ciba Geigy Ag | 3-cyclopentyl ethers of 7alpha-methyl-3,16alpha,17(alpha and beta)-trihydroxy-delta 1,3,5(10)-estratriene,their manufacture and estrogenic pharmaceutical compositions containing them |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US4666885A (en) | 1985-02-08 | 1987-05-19 | Fernand Labrie | Combination therapy for treatment of female breast cancer |
| EP0310542B1 (de) | 1987-10-01 | 1994-06-08 | Schering Aktiengesellschaft | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren |
| DE3733478A1 (de) | 1987-10-01 | 1989-04-13 | Schering Ag | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore |
| GB8813353D0 (en) | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
| DE19510862A1 (de) | 1995-03-16 | 1996-09-19 | Schering Ag | Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle |
| DE19622457A1 (de) | 1996-05-24 | 1997-11-27 | Schering Ag | 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE19635525A1 (de) * | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US5866560A (en) | 1996-08-20 | 1999-02-02 | Schering Ag | 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents |
| PL334920A1 (en) | 1997-01-30 | 2000-03-27 | Dsm Nv | Composition crossclinkable by irradiation |
| DE19706061A1 (de) | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| PE20000129A1 (es) * | 1997-12-23 | 2000-03-11 | Schering Ag | 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa |
| DE19807791A1 (de) | 1998-02-19 | 1999-08-26 | Schering Ag | Kombinationspräparat aus Östrogen und Antiöstrogen |
| DE10019171A1 (de) | 2000-04-07 | 2001-10-18 | Schering Ag | Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe |
| US7378406B2 (en) | 2000-10-18 | 2008-05-27 | Schering Ag | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| DE10159217A1 (de) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
| US20040242551A1 (en) | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
-
2001
- 2001-11-27 DE DE10159217A patent/DE10159217A1/de not_active Withdrawn
-
2002
- 2002-11-26 PE PE2002001136A patent/PE20030727A1/es not_active Application Discontinuation
- 2002-11-27 AU AU2002360949A patent/AU2002360949A1/en not_active Abandoned
- 2002-11-27 RU RU2004119437/04A patent/RU2285009C2/ru not_active IP Right Cessation
- 2002-11-27 DE DE50212302T patent/DE50212302D1/de not_active Expired - Lifetime
- 2002-11-27 CN CNB2004100861882A patent/CN1325507C/zh not_active Expired - Fee Related
- 2002-11-27 MX MXPA04005015A patent/MXPA04005015A/es active IP Right Grant
- 2002-11-27 TW TW091134468A patent/TWI256891B/zh not_active IP Right Cessation
- 2002-11-27 KR KR1020047008007A patent/KR100956912B1/ko not_active IP Right Cessation
- 2002-11-27 CA CA002468412A patent/CA2468412C/en not_active Expired - Fee Related
- 2002-11-27 RU RU2006120215/04A patent/RU2339643C2/ru not_active IP Right Cessation
- 2002-11-27 EP EP08075102A patent/EP1916254A3/de not_active Withdrawn
- 2002-11-27 UY UY27552A patent/UY27552A1/es not_active Application Discontinuation
- 2002-11-27 AR ARP020104555A patent/AR037674A1/es active IP Right Grant
- 2002-11-27 AT AT02795080T patent/ATE396198T1/de active
- 2002-11-27 EP EP02795080A patent/EP1448591B1/de not_active Expired - Lifetime
- 2002-11-27 JP JP2003547421A patent/JP2005513039A/ja active Pending
- 2002-11-27 WO PCT/EP2002/013484 patent/WO2003045972A1/de active IP Right Grant
- 2002-11-27 IL IL16220002A patent/IL162200A0/xx unknown
- 2002-11-27 BR BR0214469-7A patent/BR0214469A/pt not_active IP Right Cessation
- 2002-11-27 ES ES02795080T patent/ES2307819T3/es not_active Expired - Lifetime
- 2002-11-27 US US10/305,418 patent/US7018994B2/en not_active Expired - Fee Related
- 2002-11-27 CN CNB028275837A patent/CN100558741C/zh not_active Expired - Fee Related
- 2002-11-27 PT PT02795080T patent/PT1448591E/pt unknown
- 2002-11-27 DK DK02795080T patent/DK1448591T3/da active
- 2002-11-27 PL PL369171A patent/PL207955B1/pl not_active IP Right Cessation
-
2004
- 2004-05-27 IL IL162200A patent/IL162200A/en not_active IP Right Cessation
- 2004-06-24 ZA ZA200405029A patent/ZA200405029B/xx unknown
- 2004-06-25 NO NO20042694A patent/NO326241B1/no not_active IP Right Cessation
- 2004-09-29 ZA ZA200407868A patent/ZA200407868B/xx unknown
- 2004-10-04 NO NO20044192A patent/NO20044192L/no not_active Application Discontinuation
-
2005
- 2005-01-20 JP JP2005013016A patent/JP4335820B2/ja not_active Expired - Fee Related
- 2005-07-26 US US11/188,992 patent/US7538100B2/en not_active Expired - Fee Related
- 2005-11-03 HK HK05109797.1A patent/HK1077832A1/xx not_active IP Right Cessation
- 2005-12-08 HK HK05111269A patent/HK1079215A1/xx not_active IP Right Cessation
-
2006
- 2006-08-17 JP JP2006222528A patent/JP2006306896A/ja active Pending
-
2008
- 2008-08-21 CY CY20081100893T patent/CY1108279T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200405029B (en) | 17α-Alkyl-17β-oxy-estratrienes and intermediates for the production thereof, and use of said 17α-alkyl-17β-oxy-estratrienes for producing medicaments and pharmaceutical preparations | |
| AU2002365516A1 (en) | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | |
| NO20041277L (no) | Farmasoytiske preparater for behandling av astma. | |
| EG25011A (en) | Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments. | |
| IL191790B (en) | The history of xanthine, their production and their use as medicines | |
| HUP0401293A3 (en) | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments | |
| HUP0400200A3 (en) | Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof | |
| AU2002337047A1 (en) | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments | |
| HK1070053A1 (en) | Sulphonamide derivatives, the preparation thereof and the application of same as medicaments | |
| HUP0401201A3 (en) | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments | |
| HUP0700039A2 (en) | Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation | |
| EG24784A (en) | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments and pharmaceutical comprising them. | |
| AU2003293593A8 (en) | Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration | |
| AU777185C (en) | Pharmaceutical form of administration for peptides, methods for its production and use | |
| AU2002312897A1 (en) | Drugs for the treatment of the alzheimer disease | |
| IL162509A (en) | Use of deoxypeganine for the production of a drug for treating clinical depression | |
| AU2002333448A1 (en) | Derivatives of C2-substituted indan-1-ol systems, methods for the production thereof and their use as medicaments | |
| IL158587A0 (en) | Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof | |
| AU2003294952A1 (en) | 3,3-dimethyl-8-oxoisoquinolines for medical purposes, methods for the production thereof, medicaments containing said compounds and the use of the same | |
| PL375762A1 (en) | Nasallly applicable pharmaceutical preparation and the production thereof | |
| GB0109384D0 (en) | Pharmaceutical products, preparation and uses thereof | |
| AU2002328326A1 (en) | 1-alkyl-2-aryl-benzimidazole derivatives, their use for producing medicaments and pharmaceutical preparations containing said derivatives | |
| AU2002252987A1 (en) | Method for the continuous production of medicaments for inhalation | |
| HUP0303873A3 (en) | Mikanolide derivatives, process for their preparation and their therapeutic uses as a medicine | |
| NO20040403L (no) | Stabil polymorf av flibanserin, teknisk fremgangsmåte for fremstilling derav og anvendelse derav for fremstlling av medikamenter |